SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ALL who wrote (4287)5/11/1998 6:02:00 PM
From: mod  Read Replies (1) of 6136
 
ú New protease inhibitor scrips were down 1.8% over last week's level. Agouron's market share of new protease inhibitor prescriptions was 33.5%, up from 31.8% last week.
ú Total protease inhibitor scrips were up 1.9%, and Agouron's market share was 31.5%, up from 31.0% the week prior.
ú Refill protease inhibitor scrips were up 3.9% versus last week. Viracept's market share of refills was 30.5% for the week of May 1, unchanged from last week.

Dennis
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News